



Dear Family Member,

A member of your family has been identified as having a genetic mutation in the **MSH3 gene**. Mutations in this gene are known to be associated with an increased risk for certain cancers. This means that other family members are at risk to carry this same gene mutation and hence at an increased risk for certain cancers. This letter has been written to summarize information regarding MSH3 mutations.

Unlike other hereditary cancer syndromes, MSH3 related cancer predisposition is inherited in a recessive manner, which means both copies of the MSH3 gene in each cell have mutations in order to be at an elevated risk for cancer. Carriers of a recessive genetic condition have one working and one non-working copy of the gene. Individuals who have one *mutation* on MSH3 (carriers), are not currently believed to have an increased cancer risk. Individuals with two *mutations* in the MSH3 gene have an increased risk for developing colon polyps and colorectal cancer. Other features may include duodenal polyps, astrocytoma, thyroid adenoma, and uterine leiomyoma, but further studies are needed to confirm this. Individuals with two mutations may benefit from increased and early colonoscopy screening.

Understanding risk is an important tool in prevention and management of cancer. It is important to note that many individuals with MSH3 mutations will never develop cancer over their lifetime. When one inherits an MSH3 mutation, he/she is not inheriting cancer; rather they are inheriting a predisposition to cancer.

**We strongly recommend that you and all persons in your family who are at risk for carrying the MSH3 gene mutation consider scheduling an appointment for cancer genetic counseling to discuss the benefits and limitations of genetic testing.** To pursue cancer genetic testing, it is helpful if you have a copy of your family member's genetic testing report indicating that they have an MSH3 mutation. Also, reproductive partners of patients who are positive for MSH3 gene mutation(s) may also consider genetic testing for MSH3 to determine if their children are at risk for having two MSH3 mutations.

GeneScreen is available to discuss this information in more detail with you and coordinate appropriate testing. Please visit the following website to submit your request for genetic counseling: <https://hipaa.jotform.com/200926739003048>. You can also contact Genescreen directly at 908-766-2800 to schedule a remote consultation with a genetic counselor.

Sincerely,

Stephanie Nunziato-Virga, MS, LGC

Senior Oncology Genetic Counselor  
Genescreen

Jill Chisholm, APN

President  
Genescreen